Unknown

Dataset Information

0

Disruption of the glucagon receptor increases glucagon expression beyond α-cell hyperplasia in zebrafish.


ABSTRACT: The glucagon receptor (GCGR) is a potential target for diabetes therapy. Several emerging GCGR antagonism-based therapies are under preclinical and clinical development. However, GCGR antagonism, as well as genetically engineered GCGR deficiency in animal models, are accompanied by α-cell hyperplasia and hyperglucagonemia, which may limit the application of GCGR antagonism. To better understand the physiological changes in α cells following GCGR disruption, we performed single cell sequencing of α cells isolated from control and gcgr-/- (glucagon receptor deficient) zebrafish. Interestingly, beyond the α-cell hyperplasia, we also found that the expression of gcga, gcgb, pnoca, and several glucagon-regulatory transcription factors were dramatically increased in one cluster of gcgr-/- α cells. We further confirmed that glucagon mRNA was upregulated in gcgr-/- animals by in situ hybridization and that glucagon promoter activity was increased in gcgr-/-;Tg(gcga:GFP) reporter zebrafish. We also demonstrated that gcgr-/- α cells had increased glucagon protein levels and increased granules after GCGR disruption. Intriguingly, the increased mRNA and protein levels could be suppressed by treatment with high-level glucose or knockdown of the pnoca gene. In conclusion, these data demonstrated that GCGR deficiency not only induced α-cell hyperplasia but also increased glucagon expression in α cells, findings which provide more information about physiological changes in α-cells when the GCGR is disrupted.

SUBMITTER: Kang Q 

PROVIDER: S-EPMC9719020 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Disruption of the glucagon receptor increases glucagon expression beyond α-cell hyperplasia in zebrafish.

Kang Qi Q   Zheng Jihong J   Jia Jianxin J   Xu Ying Y   Bai Xuanxuan X   Chen Xinhua X   Zhang Xiao-Kun XK   Wong F Susan FS   Zhang Chao C   Li Mingyu M  

The Journal of biological chemistry 20221109 12


The glucagon receptor (GCGR) is a potential target for diabetes therapy. Several emerging GCGR antagonism-based therapies are under preclinical and clinical development. However, GCGR antagonism, as well as genetically engineered GCGR deficiency in animal models, are accompanied by α-cell hyperplasia and hyperglucagonemia, which may limit the application of GCGR antagonism. To better understand the physiological changes in α cells following GCGR disruption, we performed single cell sequencing of  ...[more]

Similar Datasets

2022-10-26 | GSE179894 | GEO
| PRJNA745553 | ENA
| S-EPMC4598637 | biostudies-literature
| S-EPMC5347591 | biostudies-literature
| S-EPMC298791 | biostudies-literature
| S-EPMC3609565 | biostudies-literature
| S-EPMC8206958 | biostudies-literature
| S-EPMC2743461 | biostudies-literature
| S-EPMC6581654 | biostudies-literature
2017-05-01 | GSE89636 | GEO